Leflunomide Related Compound B
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for accurate information.
Leflunomide Related Compound B Product Information
Leflunomide Related Compound B is listed under Impurity and is intended for analytical research, quality control and pharmaceutical reference standard applications. It is associated with Leflunomide. The product is supplied by Clearsynth under CAT No. CS-T-04169.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Leflunomide Related Compound B
CAS No.
108605-62-5
CAT No.
CS-T-04169
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C12H9F3N2O2
Molecular Weight
270.21
Category
API Family
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for accurate information.
Description
Regulatory Description
Leflunomide Related Compound B is supplied with detailed characterization data compliant with regulatory guideline. Leflunomide Related Compound B can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Leflunomide.
Overview
"rac A77 1726 is the active metabolite of Leflunomide, a potent disease-modifying antirheumatic drug used in the treatment of rheumatoid arthritis. LEF-M interferes with dendritic cell function. The second Phase III study evaluating the efficacy of Genzyme’s teriflunomide therapy against relapsing forms of multiple sclerosis found the once-daily oral drug to be no less effective than injectable interferon beta 1a (Rebif®). "
Synonyms
Leflunomide Related Compound B
Application Notes
"rac A77 1726 is the active metabolite of Leflunomide, a potent disease-modifying antirheumatic drug used in the treatment of rheumatoid arthritis. LEF-M interferes with dendritic cell function. The second Phase III study evaluating the efficacy of Genzyme’s teriflunomide therapy against relapsing forms of multiple sclerosis found the once-daily oral drug to be no less effective than injectable interferon beta 1a (Rebif®). "
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.